Wall Street analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Evoke Pharma’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.18). Evoke Pharma reported earnings per share of ($0.18) in the same quarter last year, which suggests a negative year-over-year growth rate of 22.2%. The company is scheduled to announce its next earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that Evoke Pharma will report full year earnings of ($1.00) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.96). For the next financial year, analysts expect that the business will report earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.13). During the same period in the previous year, the company earned ($0.29) EPS.

Several research analysts have recently weighed in on EVOK shares. FBR & Co reaffirmed a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Monday, October 30th. ValuEngine cut shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a report on Thursday, October 12th. Seaport Global Securities reaffirmed a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Friday, October 6th. Finally, Northland Securities reiterated a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Evoke Pharma has a consensus rating of “Buy” and an average price target of $9.00.

Evoke Pharma (EVOK) traded up $0.06 during trading on Friday, hitting $2.64. 95,900 shares of the stock traded hands, compared to its average volume of 404,490. Evoke Pharma has a 52-week low of $1.42 and a 52-week high of $4.55.

An institutional investor recently raised its position in Evoke Pharma stock. Vanguard Group Inc. lifted its position in shares of Evoke Pharma Inc (NASDAQ:EVOK) by 15.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 523,650 shares of the specialty pharmaceutical company’s stock after purchasing an additional 68,544 shares during the period. Vanguard Group Inc. owned 3.40% of Evoke Pharma worth $1,341,000 as of its most recent SEC filing. 13.64% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/08/brokerages-anticipate-evoke-pharma-inc-evok-will-announce-earnings-of-0-22-per-share.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.